Compare ATS & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | XENE |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | 2023 | 2014 |
| Metric | ATS | XENE |
|---|---|---|
| Price | $30.99 | $41.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $35.00 | ★ $54.09 |
| AVG Volume (30 Days) | 183.5K | ★ 793.5K |
| Earning Date | 02-04-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,048,319,324.00 | $7,500,000.00 |
| Revenue This Year | $16.92 | N/A |
| Revenue Next Year | $5.13 | N/A |
| P/E Ratio | $221.51 | ★ N/A |
| Revenue Growth | ★ 1.80 | N/A |
| 52 Week Low | $20.90 | $26.74 |
| 52 Week High | $32.73 | $46.60 |
| Indicator | ATS | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 47.44 |
| Support Level | $30.21 | $40.74 |
| Resistance Level | $31.83 | $43.67 |
| Average True Range (ATR) | 1.20 | 1.53 |
| MACD | 0.16 | 0.09 |
| Stochastic Oscillator | 85.33 | 34.80 |
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.